Enterprise Value

1.87B

Cash

137.6M

Avg Qtr Burn

N/A

Short % of Float

5.60%

Insider Ownership

6.29%

Institutional Own.

73.30%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AGAMREE® (Vamorolone) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

Approved

Quarterly sales

FIRDAPSE®(Amifampridine) Details
Autoimmune disease, Lamber-Eaton myasthenic syndrome

Approved

Quarterly sales

FIRDAPSE®(Amifampridine) Details
Lamber-Eaton myasthenic syndrome

PDUFA

Approval decision

FIRDAPSE® (Amifampridine) Details
Autoimmune disease, Neuromuscular disease

Failed

Discontinued